VenatoRx Pharmaceuticals Revenue and Competitors

Claim your profile

Location

$107M

Total Funding

Pharma

Industry

Estimated Revenue & Valuation

  • VenatoRx Pharmaceuticals's estimated annual revenue is currently $15.9M per year.(i)
  • VenatoRx Pharmaceuticals received $42.0M in venture funding in July 2017.
  • VenatoRx Pharmaceuticals's estimated revenue per employee is $201,000
  • VenatoRx Pharmaceuticals's total funding is $107M.

Employee Data

  • VenatoRx Pharmaceuticals has 79 Employees.(i)
  • VenatoRx Pharmaceuticals grew their employee count by -12% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$41.4M206-6%N/AN/A
#2
$62.5M31135%N/AN/A
#3
$4.7M5730%N/AN/A
#4
$1110.5M5525-10%N/AN/A
#5
$45.4M226-1%N/AN/A
#6
$11.7M5816%N/AN/A
#7
$13.7M6842%N/AN/A
#8
$17.3M8637%N/AN/A
#9
$45.5M21912%N/AN/A
#10
$4.8M58-13%N/AN/A

Led by a world-class team of pharmaceutical veterans, VenatoRx is a private pharmaceutical company that is developing a new wave of anti-infective products to address increasing medical needs. VenatoRx's lead product, VNRX-5133, is an injectable broad-spectrum beta-lactamase inhibitor (BLI) that directly inhibits all four Ambler classes of beta-lactamases. Early clinical studies of cefepime/VNRX-5133 have been completed and VenatoRx plans to start Phase 3 pivotal trials in the second half of 2018. In addition, VenatoRx has a broad pipeline of preclinical programs, including a broad-spectrum orally bioavailable BLI, a novel class of Penicillin-Binding Protein (PBP) inhibitors that are impervious to beta-lactamase-driven resistance, and novel antiviral agents.

keywords:Biotechnology,Healthcare,Pharmaceuticals

$107M

Total Funding

79

Number of Employees

$15.9M

Revenue (est)

-12%

Employee Growth %

N/A

Valuation

N/A

Accelerator

VenatoRx Pharmaceuticals News

2022-03-30 - Venatorx Pharmaceuticals Raises Series C Financing

Venatorx Pharmaceuticals, Inc., a Malvern, PA-based private, clinical-stage pharmaceutical company focused on improving health outcomes for...

2022-03-30 - AMR Action Fund Announces First Investments in Adaptive ...

"Adaptive Phage Therapeutics and Venatorx Pharmaceuticals are poised to change the treatment landscape for drug-resistant infections," said AMR...

2022-03-30 - Venatorx Pharmaceuticals Raises Series C Financing Led by ...

Venatorx is a private, clinical-stage pharmaceutical company focused on improving health outcomes for patients with multidrug-resistant...

2019-09-07 - VenatoRx Pharmaceuticals Names Joseph C. Larsen, Ph.D. Vice President, Strategic Portfolio Development

MALVERN, Pa.--(BUSINESS WIRE)--. VenatoRx Pharmaceuticals today announced that Joseph C. Larsen, Ph.D. has joined the Company as ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$3.5M8142%N/A
#2
$28.1M8521%$41.7M
#3
$7.5M88-6%N/A
#4
$12.5M89-17%N/A
#5
$18.2M9142%N/A

VenatoRx Pharmaceuticals Funding

DateAmountRoundLead InvestorsReference
2017-07-26$42.0MBVersant VenturesArticle